Publications by authors named "Walter Stadler"

Claim this Profile
T
The comeback of orchiectomy in advanced prostate cancer- is that feasible?
Alon Lazarovich, Walter M Stadler, Scott Eggener, Samuel Tremblay, Ashley Page

Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, Begoña Mellado, Takeo Kosaka, Walter M Stadler

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation-Based Cost Savings With Cabozantinib Capsules.
Austin Wesevich, Walter M Stadler, Mark J Ratain

JAMA Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Athalia R Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha, Walter M Stadler

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma.
Rohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, Fauzia Arif, Scott E Eggener, Walter M Stadler

Int J Radiat Oncol Biol Phys· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Thomas Powles, Toni K Choueiri, Laurence Albiges, Katriina Peltola, Guillermo de Velasco, Walter M Stadler

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Stephanie A Berg, Salvatore La Rosa, Tian Zhang, Phillip M Pierorazio, Laurence Albiges, Walter M Stadler

Urol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
Suzanne George, Nancy Campbell, Shauna L Hillman, Elizabeth S Harlos, David W J Stein, Walter M Stadler

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, Usama S Gergis, Martin E Guiterrez, Walter M Stadler

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Daniel Huang, Connor Lynch, Lucas M Serra, Randy F Sweis, Paul J Chang, Walter M Stadler

Clin Transl Radiat Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
Walter M Stadler, Theodore G Karrison

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Walter M Stadler

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the doses of cancer drugs after usual dose finding.
Garth W Strohbehn, Walter M Stadler, Philip S Boonstra, Mark J Ratain

Clin Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bladder-Preserving Trimodality Therapy With Capecitabine.
Connor Lynch, Randy F Sweis, Parth Modi, Piyush K Agarwal, Russell Z Szmulewitz, Walter M Stadler

Clin Genitourin Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Channing J Paller, Pedro C Barata, Justin Lorentz, Leonard J Appleman, Andrew J Armstrong, Walter M Stadler

Prostate· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Jason P Meier, Hannah J Zhang, Richard Freifelder, Mohammed Bhuiyan, Phillip Selman, Walter Stadler

Molecules· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enrollment Barriers for Molecular Targeted Trials.
Koosha Paydary, Alli DeLuca, Rahul Aggarwal, Lauren Wall, Walter M Stadler

JAMA Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Priyanka V Chablani, Theodore Karrison, Walter M Stadler

Clin Genitourin Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
David J VanderWeele, Masha Kocherginsky, Sabah Munir, Brenda Martone, Vinay Sagar, Walter M Stadler

Clin Genitourin Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Nizar M Tannir, Neeraj Agarwal, Camillo Porta, Nicola J Lawrence, Robert Motzer, Walter M Stadler

JAMA Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases.
Ajit Paintal, Melissa Y Tjota, Peng Wang, Carrie Fitzpatrick, Pankhuri Wanjari, Walter M Stadler

Am J Surg Pathol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging targets in kidney cancer: opportunities for drug development.
Walter Stadler

Clin Adv Hematol Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Anthony V Serritella, Daniel Shevrin, Elisabeth I Heath, James L Wade, Elia Martinez, Walter M Stadler

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
Bradley A McGregor, Wanling Xie, Elio Adib, Walter M Stadler, Yousef Zakharia

JCO Precis Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis